Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the ...
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial) Single-cell transcriptomic ...
New Haven, Conn. — Cancer fighting T-cells, the immune system’s primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback